Clinical Trial Update: Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma [Phase 2]

View source ↗

Summary

NCI-sponsored Phase 2 trial evaluating ibrutinib in patients with refractory metastatic cutaneous melanoma; results were posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Melanoma

Drugs mentioned

• Ibrutinib (ibrutinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Melanoma, Recurrent Cutaneous Melanoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2019-06-18